🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔍 Real-world study: Abiraterone, enzalutamide & apalutamide show similar survival in high-risk metastatic prostate cancer. Choose based on side effects! 💊 #ProstateCancer #Oncology pubmed.ncbi.nlm.nih.gov/39417629/

📊 Study: Deeper PSA drops (≤0.02 ng/mL) & slower time to nadir (>12 months) predict better outcomes with ARSI therapy in metastatic prostate cancer! 🎯 #ProstateCancer #Oncology pubmed.ncbi.nlm.nih.gov/39389903/

Great day on the green⛳️Perfect weather for golf and camaraderie🌞

🔍 10-year result of P3 RCT: 9mo hormone therapy after brachytherapy shows no survival benefit in intermediate-risk prostate cancer. pubmed.ncbi.nlm.nih.gov/39551103/

🌏 Honored to host Prof. Gavin Pettigrew (Cambridge Univ.) in Japan for his insightful lecture on UK organ transplantation. Thank you for sharing your expertise! 🙌

The #UroSoMe dinner! Fun group of urologists from all around the world joining hands to do meaningful work together! #EAU25

🧠 New case: Person with prostate cancer developed rare paraneoplastic nerve syndrome or COVID-related OMS. Symptoms improved after treating both conditions! 🔬 #neurology #research​​ onlinelibrary.wiley.com/doi/10.1002/ij…

🔬 scRNA-seq & spatial transcriptomics reveal bladder cancer heterogeneity, treatment resistance mechanisms & gender differences in tumor microenvironment. New potential for personalized therapy! 🧫 #BladderCancer​​​​​​​​​​​​​​​​ journals.sagepub.com/doi/10.1177/23…

🔬 Study: Lung Immune Prognostic Index (LIPI) effectively predicts outcomes after radical nephroureterectomy in people with upper tract urothelial carcinoma. Accuracy improves with pathological staging. #UTUC #Urology 🧫​​​​​​​​​​​​​​​​ iv.iiarjournals.org/content/39/2/8…

🔬 Study: In mCSPC patients, lung-only metastases showed better outcomes than other visceral sites. Bone metastasis volume, not lung involvement, significantly affected survival with ARSI therapy. #ProstateCancer #Oncology 🧪​​​​​​​​​​​​​​​​ sciencedirect.com/science/articl…

📊 Study shows larger ureteral access sheaths (13/15Fr vs 11/13Fr) significantly reduce intrarenal pressure during lithotripsy with LithoVue™ Elite ureteroscope. Smaller sheaths associated with higher pressure. #Urology #Lithotripsy 🔬​​​​​​​​​​​​​​​​ link.springer.com/article/10.100…

📊 Study: Physicians and patients in Japan value efficacy in prostate cancer treatment, but differ on outcomes—doctors prioritize survival while patients focus on preventing metastasis spread and PSA elevation. #SharedDecisionMaking link.springer.com/article/10.100…

💉 Study shows single IV dose of isepamicin alone (without levofloxacin) effectively prevents infections after transrectal prostate biopsy, even in high-risk patients. Only 0.5% infection rate overall. #AntimicrobialStewardship jiac-j.com/article/S1341-…

📈 Study validates stage III bladder cancer substaging: IIIB (pTanyN2-3) shows worse outcomes than IIIA after radical cystectomy. No survival difference between pT3-4aN0 and pTanyN1 within IIIA. Guides treatment decisions. #BladderCancer onlinelibrary.wiley.com/doi/10.1111/ij…

⚛️ Study: Completing all 6 cycles of radium-223 therapy significantly improves survival in metastatic CRPC patients (18 vs 5 months). Earlier initiation before docetaxel, bone pain, or high PSA levels increases completion rates. #ProstateCancer academic.oup.com/jjco/advance-a…

🔬 Real-world study: 67% of Japanese patients with advanced urothelial carcinoma eligible for maintenance avelumab after platinum chemo. Median PFS 10.2 months, OS not reached. Liver mets and CRP are key prognostic factors. #BladderCancer academic.oup.com/jjco/advance-a…

🤖 First study of "Saroa" surgical robot for prostate surgery shows promise with novel tactile feedback feature. Longer operating times than da Vinci Xi but safe, with gentler tissue handling when feedback activated. Needs more research. #RoboticSurgery nature.com/articles/s4159…

📊 Study finds apalutamide may provide less benefit for people with mCSPC having fewer bone metastases. No significant survival improvement seen in patients with ≤2 bone lesions, while those with ≥3 show greater benefit. Count matters! #ProstateCancer acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

Had an unforgettable experience at #AUA25!🇺🇸 So grateful to be part of such a special field. Thank you for the insightful sessions and the chance to connect with so many brilliant and passionate individuals driving the future of Urology!🌎

🎉Our work was published at European Urology today! 🪭Randomized noninferiority trial: Flexible and Navigable Suction Ureteral Access Sheath flexible ureteroscopy #FANS #fURS vs #miniPCNL in 2-3cm renal stone 🔗 doi.org/10.1016/j.euru… #GuohuaZeng #WeiZhu #fansofFANS #UroSoMe